VERO Venus Concept

Venus Concept to Release First Quarter of Fiscal Year 2020 Financial Results on May 14, 2020

Venus Concept to Release First Quarter of Fiscal Year 2020 Financial Results on May 14, 2020

TORONTO, April 15, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that first quarter of fiscal year 2020 financial results will be released after the market closes on Thursday, May 14, 2020.

Management will host a conference call at 5:00 p.m. Eastern Time on May 14, 2020 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13702282. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13702282. The webcast will be archived at ir.venusconcept.com.

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 29 direct markets. Venus Concept focuses its product sales strategy on a subscription-based business model in North America and in its well-established direct global markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Freeze Plus, and Venus Bliss. Venus Concept’s hair restoration systems includes NeoGraft®, an automated hair restoration system that facilitates the harvesting of follicles during a FUE process and the ARTAS® and ARTAS iX® Robotic Hair Restoration Systems, which harvest follicular units directly from the scalp and create recipient implant sites using proprietary algorithms. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, and Aperture Venture Partners.

Investor Relations Contact:
Westwicke Partners on behalf of Venus Concept
Mike Piccinino, CFA
 
EN
15/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Venus Concept

 PRESS RELEASE

Venus Concept Raises a Total of Approximately $2.7 Million in Gross Pr...

Venus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common Stock TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 386,700 shares of common stock at a purchase price of $4.06 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for...

 PRESS RELEASE

Venus Concept Announces $1.5 Million Registered Direct Offering of Com...

Venus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 386,700 shares of common stock at a purchase price of $4.06 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 14, 2025, sub...

 PRESS RELEASE

Venus Concept Announces Closing of $1.1 Million Registered Direct Offe...

Venus Concept Announces Closing of $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules TORONTO, April 10, 2025 (GLOBE NEWSWIRE) --  Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 328,573 shares of common stock at a purchase price of $3.50 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. ...

 PRESS RELEASE

Venus Concept Announces $1.1 Million Registered Direct Offering of Com...

Venus Concept Announces $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules TORONTO, April 09, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 328,573 shares of common stock at a purchase price of $3.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 10, 2025, sub...

 PRESS RELEASE

Venus Concept to Release First Quarter of Fiscal Year 2025 Financial R...

Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025 TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch